Sun Pharma Advanced Research Company Share Price Today (SPARC)
TODAY IN ONE LINE
SPARC fell 2.8% on light volume, lagging Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹6,782.5 Cr., it trades at a P/E of 4.39. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Sun Pharma Advanced Research Company flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 6716.0% and Profit up 3047.0%
- ●High Capital EfficiencyROCE of 164.0% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 279.0%
- ●Healthy Operating MarginsOPM is structurally strong at 85.1%
- ●Reasonable ValuationTrading at a moderate P/E of 5.0x
- ●High Promoter HoldingPromoters hold 65.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Sun Pharma Advanced Research Company News
What changed recently?
Recent events, corporate actions, and announcements.
Sun Pharma Advanced Research Company Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sun Pharma Advanced Research Company Limited, framed against the sector median so the premium or discount is obvious at a glance.
Sun Pharma Advanced Research Company Limited trades at a P/E of 4.39× and P/B of 5.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Sun Pharma Advanced Research Company Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sun Pharma Advanced Research Company Limited — derived from the live tape, not yesterday's close.
Sun Pharma Advanced Research Company Limited last traded at ₹208.96 with an intraday range of ₹207.41–₹215.06 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹208.96| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 228.84 | +19.88 | +9.52% |
| R3 | 221.19 | +12.23 | +5.85% |
| R2 | 218.13 | +9.17 | +4.39% |
| R1 | 213.54 | +4.58 | +2.19% |
| PIVOT | 210.48 | 1.52 | 0.73% |
| CURRENT | 208.96 | — | — |
| S1 | 205.89 | -3.07 | -1.47% |
| S2 | 202.83 | -6.13 | -2.94% |
| S3 | 198.24 | -10.72 | -5.13% |
| S4 | 190.59 | -18.37 | -8.79% |
SPARC is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹212.51–₹215.06
Trading Below opening range, showing Bearishness
Sun Pharma Advanced Research Company Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Sun Pharma Advanced Research Company Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Sun Pharma Advanced Research Company Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,782.5 Cr. and reported EPS of ₹49.21.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 72 | 1,879 ▲ 2518.3% |
| Sales Growth YoY %Derived | -5.00% | 2,518.32% |
| Other Income | 2 | 11 ▲ 511.7% |
| Total Income | 74 | 1,890 ▲ 2469.5% |
| 23 | 24 ▲ 2.1% | |
| Gross ProfitDerived | 49 | 1,856 ▲ 3714.1% |
| Gross Margin %Derived | 67.79% | 98.74% |
| 372 | 257 ▼ 30.9% | |
| EBITDA (Operating Profit)Derived | -323 | 1,599 ▲ 594.8% |
| OPM %Derived | -450.24% | 85.08% |
| 21 | 32 ▲ 49.2% | |
| Profit Before Tax (PBT) | -343 | 1,553 ▲ 553.1% |
| -0 | -0 ▲ 29.6% | |
| Effective Tax %Derived | 0.08% | -0.01% |
| Total Profit for Period | -343 | 1,553 ▲ 553.5% |
| Net Profit (Owner's PAT)Derived | -343 | 1,553 ▲ 553.5% |
| Net Profit Margin %Derived | -477.23% | 82.65% |
| PAT Growth YoY %Derived | 11.54% | 553.48% |
| Earnings Per Share (EPS ₹) | -10.56 | 47.86 ▲ 553.2% |
| Diluted Shares Outstanding (Cr) | 32 | 32 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 3 ▲ 1452.6% |
| Total Expenses (incl. D&A & Interest) | 416 | 337 ▼ 19.0% |
| Material Cost % of RevenueDerived | 32.21% | 1.26% |
| Employee Cost % of RevenueDerived | 213.99% | 6.28% |
| Other Cost % of RevenueDerived | 304.04% | 7.39% |
| Interest Coverage (x)Derived | -37.12x | 46.54x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 76 | 72 ▼ 5.0% | 1,879 ▲ 2518.3% | |
| Sales Growth YoY %Derived | — | -5.00% | 2,518.32% | |
| Other Income | 29 | 2 ▼ 93.9% | 11 ▲ 511.7% | |
| Total Income | 105 | 74 ▼ 30.0% | 1,890 ▲ 2469.5% | |
28 | 23 ▼ 17.8% | 24 ▲ 2.1% | ||
| Gross ProfitDerived | 47 | 49 ▲ 2.6% | 1,856 ▲ 3714.1% | |
| Gross Margin %Derived | 62.77% | 67.79% | 98.74% | |
450 | 372 ▼ 17.3% | 257 ▼ 30.9% | ||
| EBITDA (Operating Profit)Derived | -402 | -323 ▲ 19.6% | 1,599 ▲ 594.8% | |
| OPM %Derived | -532.23% | -450.24% | 85.08% | |
14 | 21 ▲ 50.9% | 32 ▲ 49.2% | ||
| Profit Before Tax (PBT) | -387 | -343 ▲ 11.4% | 1,553 ▲ 553.1% | |
0 | -0 ▼ 171.1% | -0 ▲ 29.6% | ||
| Effective Tax %Derived | -0.10% | 0.08% | -0.01% | |
| Total Profit for Period | -387 | -343 ▲ 11.5% | 1,553 ▲ 553.5% | |
| Net Profit (Owner's PAT)Derived | -387 | -343 ▲ 11.5% | 1,553 ▲ 553.5% | |
| Net Profit Margin %Derived | -512.52% | -477.23% | 82.65% | |
| PAT Growth YoY %Derived | — | 11.54% | 553.48% | |
| Earnings Per Share (EPS ₹) | -11.93 | -10.56 ▲ 11.5% | 47.86 ▲ 553.2% | |
| Diluted Shares Outstanding (Cr) | 32 | 32 ▲ 0.0% | 32 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 195.0% | 3 ▲ 1452.6% | |
| Total Expenses (incl. D&A & Interest) | 492 | 416 ▼ 15.4% | 337 ▼ 19.0% | |
| Material Cost % of RevenueDerived | 37.23% | 32.21% | 1.26% | |
| Employee Cost % of RevenueDerived | 187.74% | 213.99% | 6.28% | |
| Other Cost % of RevenueDerived | 407.25% | 304.04% | 7.39% | |
| Interest Coverage (x)Derived | -245.33x | -37.12x | 46.54x |
Sun Pharma Advanced Research Company segment analysis : revenue and profit mix.
Disclosed business segments at Sun Pharma Advanced Research Company with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sun Pharma Advanced Research Company discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Sun Pharma Advanced Research Company Limited.
Our AI distills the core fundamental drivers supporting Sun Pharma Advanced Research Company Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Sun Pharma Advanced Research Company Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 84.53% far exceeds pharmaceutical sector average, exceptional cost discipline
P/E ratio 4.98x significantly below sector median 28.20x, offering deep valuation discount
High promoter holding 65.67% signals strong founder commitment and long-term vision
ROE 279.00% and ROCE 164.00% reflect strong earnings relative to equity base
Robust clinical-stage pipeline across oncology, neurodegeneration, immunology therapeutic areas
Key Risks.
Quarterly net income negative ₹51.9 Cr, persistent losses erode shareholder value
Quarterly sales declined 42.60% YoY, indicating severe revenue contraction and market challenges
Operating cash flow negative ₹238.89 Cr in FY2026 despite ₹1,552 Cr PAT, severe cash conversion failure
Cash flow per share negative ₹7.36 annually, liquidity strain threatens operations
Zero dividend yield and no shareholder distributions limit income-focused investor appeal
Flip Conditions.
Valuation risk. a P/E above 6 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 274% would indicate weaker capital compounding.
Sun Pharma Advanced Research Company Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sun Pharma Advanced Research Company Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Sun Pharma Advanced Research Company Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Sun Pharma Advanced Research Company Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Sun Pharma Advanced Research Company Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sun Pharma Advanced Research Company Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sun Pharma Advanced Research Company Limited stood at 44.1% of traded volume, against a 20-day average of 37.0%.
Sun Pharma Advanced Research Company announcements: results, concalls, ratings, M&A.
Filings Sun Pharma Advanced Research Company sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sun Pharma Advanced Research Company files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 80 documents below.
Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026 along…
Change in Director(s)
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company.
Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication of 21st Annual General Meeting of the…
Updates
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding 'Intimation of the 21st Annual General Meeting of the Company'.
Investor decks & rating reports.
Sun Pharma Advanced Research Company dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sun Pharma Advanced Research Company has declared, sequenced by announce and record date.
Sun Pharma Advanced Research Company corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sun Pharma Advanced Research Company Limited: business, sector, key facts.
What Sun Pharma Advanced Research Company Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sun Pharma Advanced Research Company Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SPARC, BSE: 532872.
SPARC (Sun Pharma Advanced Research Company Limited) is a clinical-stage biopharmaceutical company headquartered in Mumbai, India, focusing on the research and development of novel pharmaceutical products for global markets. Their core therapeutic areas of concentration are oncology, neurodegeneration, and immunology, reflecting a commitment to addressing significant unmet medical needs across diverse disease areas.
A significant portion of SPARC's business involves advancing a robust pipeline of drug candidates through various clinical trial phases. This includes Elepsia XR for epilepsy, PDP-716 for open-angle glaucoma, and Sezaby for neonatal seizures. These products represent different stages of development, highlighting SPARC's commitment to a diversified approach to drug discovery and development.
In the oncology space, SPARC is actively pursuing the development of Vodobatinib, a c-ABL inhibitor. This compound is in phase 2 clinical trials for Parkinson's disease, has completed phase 1 trials for Lewy body dementia, and is currently in preclinical development for Alzheimer's disease. Further, they are developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, targeting refractory chronic myelogenous leukemia, also in phase 2 clinical trials.
SPARC's commitment to immunology is showcased by the development of Vibozilimod (SCD-044), a selective S1PR1 agonist currently in phase 2 trials for psoriasis and atopic dermatitis. The company also has preclinical stage candidates in development, including SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 antibody-drug conjugate (ADC) targeting multiple tumor types. This demonstrates a long-term strategic vision for growth within this therapeutic area.
In summary, SPARC's business model centers on the innovative research, development, and clinical advancement of a diverse portfolio of pharmaceutical products across several key therapeutic areas. Their pipeline, ranging from preclinical to phase 2 trials, positions them for potential future growth and market expansion in the global biopharmaceutical industry. The company's focus on unmet medical needs underscores its commitment to improving patient outcomes.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Sun Pharma Advanced Research Company Limited (SPARC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sun Pharma Advanced Research Company Limited (SPARC)?
The current share price of Sun Pharma Advanced Research Company Limited (SPARC) is ₹208.96. Today, the stock has declined by ₹5.95 (2.77%), trading in a range of ₹207.41 to ₹215.06. The stock opened at ₹214.88 with a trading volume of 9,18,663 shares.
02Is Sun Pharma Advanced Research Company Limited stock a good investment for long-term?
Sun Pharma Advanced Research Company Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,782.5 crores, P/E ratio of 4.39, ROE of 279.00%, and ROCE of 164.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sun Pharma Advanced Research Company Limited stock?
The 52-week high price of Sun Pharma Advanced Research Company Limited (SPARC) is ₹289, while the 52-week low is ₹108. Currently trading at ₹208.96, the stock is 55.8% away from its 52-week low and 27.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sun Pharma Advanced Research Company Limited stock at the current price?
Whether to buy Sun Pharma Advanced Research Company Limited stock at ₹208.96 depends on multiple factors. The stock is currently trading with a P/E ratio of 4.39 and P/B ratio of 5.09. Today's performance shows a loss of 2.77%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sun Pharma Advanced Research Company Limited and when is the next dividend?
Sun Pharma Advanced Research Company Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹208.96, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sun Pharma Advanced Research Company Limited?
Sun Pharma Advanced Research Company Limited's key financial metrics include: P/E Ratio: 4.39, P/B Ratio: 5.09, ROE: 279.00%, ROCE: 164.00%, Dividend Yield: 0.00%, EPS: ₹49.21, Book Value: ₹41.25, and Debt-to-Equity: 0.42. The company's market cap stands at ₹6,782.5 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sun Pharma Advanced Research Company Limited stock performing today in the market?
Sun Pharma Advanced Research Company Limited stock opened at ₹214.88 and is currently trading at ₹208.96, showing a decline of ₹5.95 (2.77%). The intraday high is ₹215.06 and low is ₹207.41. The trading volume stands at 9,18,663 shares, indicating moderate market participation today.
08What is the P/E ratio of Sun Pharma Advanced Research Company Limited and what does it indicate?
Sun Pharma Advanced Research Company Limited has a Price-to-Earnings (P/E) ratio of 4.39, which means investors are willing to pay ₹4.39 for every ₹1 of earnings. With an EPS of ₹49.21, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sun Pharma Advanced Research Company Limited (SPARC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.